...ning CellBIND surface is produced by a patented mi...face giving more consistent, even cell attachment,...es cell attachment and growth uunder difficult con...ium. • CellBIND may provide a more ecominic a...
...-Plex suspension array system, 100-240 V, uses xMA...s of up to 100 proteins and peptides in one microp...to 100 color-coded bead sets, each of which may be...tes, receptors, antigens, or antibodies) specific ...
FACTS from Tecan
...ually every research laboratory, the revolutionary...on accurately, inexpensively and in real time enha...compact lab analysis system includes the Luminex 1...technology which enables you to simultaneously ass...
Biology Products:(Date:12/2/2009)...s of carbon about a nanometer in diameterhave been...ultrastrong fibers, electrical wires in molecular ...ells. Thanks to a new development by researchers a...gy (NIST) and five partners, you can add one more ... of an aggressive form of breast cancer. , HER2 ...
(Date:12/2/2009)...cording to the National Institute of Health, 40 pe...abetes already have some stage of diabetic retinop...caused by leaky blood vessels, is a major cause of...he most feared diabetic complications. In fact, u...s for 10 years or more will experience some form o...
(Date:12/1/2009)...Dec. 1 GestureTek Inc. today annou...ey, portable, plug and play interactive projection...inment and touring promotions. GestureTek is the i...enabled gesture recognition technology for interac...ms. ,, Guaranteed for quality, the CUBE has TUV...
Breaking Biology News(10 mins):Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 56873 1Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 56873 2Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 56873 3Regeneron Announces September 2009 Investment Conference Presentations 56871 1Regeneron Announces September 2009 Investment Conference Presentations 56871 2BayCare Outpatient Center Opens in Westchase Florida 56869 1(Date:12/2/2009)..., Calif., Dec. 2 Peregri...ported completion of patient enrollment in a dose ...n patients with relapsed glioblastoma multiforme (...is a targeted monoclonal antibody linked to a radi...ent for GBM. Cotara specifically targets cells at...
(Date:12/2/2009)...EVILLE, Gabon, December 2 , ...s Problem and Heritage" , Coinciding with...2010 the,Gabonese Republic is hosting an internati... of safeguarding biological resources in Africa. T...tate leaders, ministers,scientific experts, priva...
(Date:12/2/2009)...BRIDGE, Mass., Dec. 2 TechConnect ...echnology development and product integration in c...e December 11th deadline for technology abstracts ...year, TechConnect World, in association with the N...he Clean Technology and Sustainable Industries Org...
(Date:12/2/2009)...GAPORE, Dec. 2 S*BIO Pte Ltd today...K2 inhibitor, SB1518, at The American Society of H...w Orleans. ,, Data will be presented on the cli...al of SB1518 detailing its safety, tolerability an...in dose levels ranging from 100 to 600 mg. These d...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5